With positive key trial, Kala Pharma's dry eye drug Eysuvis emulates approval path set by Xiidra

Mixed data from previous study readouts on its drug for short-term dry eye relief precipitated a rejection from the FDA, leaving Kala Pharmaceuticals’ fate in the hands of a third study. On Monday, that trial met its goals, setting up the Watertown, Massachusetts-based company to resubmit a marketing application in the second quarter.